Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 28Melanoma 26Carcinoma, Renal Cell 25Neoplasm Metastasis 11Lung Neoplasms 11Squamous Cell Carcinoma of Head and Neck 9Neoplasms 9Colorectal Neoplasms 9Prostatic Neoplasms 8Hodgkin Disease 8Carcinoma, Transitional Cell 7Carcinoma, Hepatocellular 7Adenocarcinoma Of Esophagus 7Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Rectal Neoplasms 6Ovarian Neoplasms 6Pancreatic Neoplasms 5Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Nasopharyngeal Carcinoma 4Multiple Myeloma 4Endometrial Neoplasms 4Clear-cell metastatic renal cell carcinoma 4Carcinoma, Merkel Cell 4Carcinoma, Basal Cell 4Brain Neoplasms 4Anus Neoplasms 4Thyroid Neoplasms 3Sarcoma, Kaposi 3

Interventions

pembrolizumab 1Nivolumab 1Immune Checkpoint Inhibitors 1DEAE-Dextran 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Oligoprogressive × Nivolumab × 30 days × Clear all
NCT05846659 2026-05-15

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

ImmuneSensor Therapeutics Inc.

Phase 2 Terminated
16 enrolled 13 charts

Oligoprogressive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡